Neurology® Podcast

Latest Episodes:

March 20 2012 Issue Mar 19, 2012

Show notes

1) Lamotrigine and aseptic meningitis and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michaela Tegan Chatman interviews Drs. Simms, Kortepeter and Avigan about their paper on lamotrigine and aseptic meningitis. Dr. Stacey Clardy is reading our e-Pearl of the week about pregnancy on the course of neuromyelitis optica. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about risk-benefit ratios. Next week, Dr. Burns will interview Drs Groopman and Hartzband about additional topics from their books and columns not previously discussed. The participants had nothing to disclose except Drs. Simms, Kortepeter, Avigan, Clardy, Burns, Groopman and Hartzband.Dr. Simms is employed at U.S. Food and Drug Administration. Dr. Kortepeter is employed at U.S. Food and Drug Administration. Dr. Avigan is employed at U.S. Food and Drug Administration. Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Groopman receives royalties from the publication of the book Your Medical Mind.Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

March 13 2012 Issue Mar 12, 2012

Show notes

1) Cognition in the minimally-conscious state and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Thomas Cochrane interviews Dr. Damian Cruse about his paper on etiology and covert cognition in the minimally-conscious state. Dr. Stacey Clardy is reading our e-Pearl of the week about Moyamoya disease. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about cognitive errors or biases that can influence our ability to diagnose. Next week, Dr. Burns will interview Drs Groopman and Hartzband about risk-benefit ratios. The participants had nothing to disclose except Drs. Cochrane, Cruse, Clardy, Burns, Groopman and Hartzband.Dr. Cochrane received royalties from the publication of the book First Aid for the Boards: Neurology.Dr. Cruse has received research support from Medical Research Council UK and the Canada Excellence Research Chair Program.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Groopman receives royalties from the publication of the book Your Medical Mind.Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

March 6 2012 Issue Mar 05, 2012

Show notes

1) AAN policy on pharmaceutical and device industry support and 2) Topic of the month: Recent book, Your medical mind: How to decide what is right for you. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Mr. John Hutchins about his paper on AAN policy on pharmaceutical and device industry support. Dr. Stacey Clardy is reading our e-Pearl of the week about CSF biomarker in Alzheimer disease. In the next part of the podcast Dr. Ted Burns interviews Drs. Groopman and Hartzband about clinical diagnostic reasoning and cognitive errors. Over the following weeks, Dr. Burns will interview Drs Groopman and Hartzband on an additional number of topics with week two about cognitive errors or biases that can influence our ability to diagnose. The participants had nothing to disclose except Mr. Hutchins, Drs. Burns, Clardy, Groopman and Hartzband.Mr. Hutchins is currently the Associate General Counsel of the American Academy of Neurology and General Councel of the American Academy of Neurology Foundation.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Groopman receives royalties from the publication of the book Your Medical Mind.Dr. Hartzband receives royalties from the publication of the book Your Medical Mind.

Delayed Recall - March 2012 Mar 01, 2012

Show notes

Chafic Karam interviewing Mark Kupersmith about selected neuro-ophthalmology topics originally posted October 2011.

February 28 2012 Issue Feb 27, 2012

Show notes

1) Fingolimod-associated macular edema and 2) Topic of the month: Paraneoplastic syndromes in neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. M. Tariq Bhatti about his paper on fingolimod-associated macular edema. Dr. Jennifer Fugate is reading our e-Pearl of the week about omega 3 fatty acids: Good for the brain. In the next part of the podcast Dr. Chafic Karam interviews Dr. Josep Dalmau about disease specific paraneoplastic disorders. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Keegan, Bhatti, Fugate, Karam and Dalmau.Dr. Keegan serves as a Section Editor for Neurology® and as Chief Editor for eMedicine and has served as a consultant for Novartis, Bionest Parners, and the FDA.Dr. Bhatti has received consultancy fees, speaker fees or honoraria from Pfizer Inc, EMD Serono, Inc., Novartis and Bayer Schering Pharma.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Dalmau serves on the editorial board of Neurology®; receives royalties from the editorial board of Up-To-Date; has filed a patent application for the use of LGI1 as a diagnostic test; has received royalties from Athena Diagnostics, Inc. for a patent re: Ma2 autoantibody test and has patents pending re: NMDA and GABAB receptor autoantibody tests (license fee payments received from EUROIMMUN AG); and receives research support from funding from EUROIMMUN AG, the NIH/NCI, and a McKnight Neuroscience of Brain Disorders award.

February 21 2012 Issue Feb 20, 2012

Show notes

1) Treatment of spinocerebellar ataxia and 2) Topic of the month: Paraneoplastic syndromes in neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Bryan Cupka interviews Dr. Theresa Zesiewicz about her paper on treatment of spinocerebellar ataxia. Dr. Jennifer Fugate is reading our e-Pearl of the week about hereditary angioedema. In the next part of the podcast Dr. Chafic Karam interviews Dr. Josep Dalmau about NMDA encephalitis. Next week, you will hear the last interview by Dr. Karam with Dr. Dalmau about other paraneoplastic syndromes in neurology. The participants had nothing to disclose except Drs. Zesiewicz, Fugate, Karam and Dalmau.Dr. Zesiewicz serves on the speakers' bureau for and has received funding for travel and speaker honoraria from Teva Pharmaceutical Industries Ltd.; serves on the editorial board of Tremor and Other Hyperkinetic Movement Disorders; serves/has served as a consultant for Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., Allergan, Inc., UCB, and Novartis; is listed as an inventor on a provisional patent on the use of nicotinic modulators in treating ataxia and imbalance held by the University of South Florida; and receives/has received research support from Pfizer Inc, the National Ataxia Foundation, the Friedreich's Ataxia Research Association, and the Bobby Allison Ataxia Research Center.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Dalmau serves on the editorial board of Neurology®; receives royalties from the editorial board of Up-To-Date; has filed a patent application for the use of LGI1 as a diagnostic test; has received royalties from Athena Diagnostics, Inc. for a patent re: Ma2 autoantibody test and has patents pending re: NMDA and GABAB receptor autoantibody tests (license fee payments received from EUROIMMUN AG); and receives research support from funding from EUROIMMUN AG, the NIH/NCI, and a McKnight Neuroscience of Brain Disorders award.

February 14 2012 Issue Feb 13, 2012

Show notes

1) Absent brainstem reflexes and 2) Topic of the month: Paraneoplastic syndromes in neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Shin Chien Beh about his paper on a 41-year-old comatose man. Dr. Jennifer Fugate is reading our e-Pearl of the week about gait freezing. In the next part of the podcast Dr. Chafic Karam interviews Dr. Josep Dalmau about common central nervous system paraneoplastic disorders. Over the next two weeks, Dr. Karam will interview Dr. Dalmau about other paraneoplastic syndromes in neurology. The participants had nothing to disclose except Drs. Burns, Fugate, Karam and Dalmau.Dr. Burns serves as Podcast Editor for Neurology®; performs EMG studies in his neuromuscular practice (30% effort); and has received research support from the Myasthenia Gravis Foundation of America and Knopp Neurosciences Inc..Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Karam serves on the editorial team for the Neurology® Resident and Fellow Section.Dr. Dalmau serves on the editorial board of Neurology®; receives royalties from the editorial board of Up-To-Date; has filed a patent application for the use of LGI1 as a diagnostic test; has received royalties from Athena Diagnostics, Inc. for a patent re: Ma2 autoantibody test and has patents pending re: NMDA and GABAB receptor autoantibody tests (license fee payments received from EUROIMMUN AG); and receives research support from funding from EUROIMMUN AG, the NIH/NCI, and a McKnight Neuroscience of Brain Disorders award.

February 7 2012 Issue Feb 07, 2012

Show notes

1) IV thrombolysis-treated ischemic stroke patients and 2) Topic of the month: Paraneoplastic syndromes in neurology. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Daniel Strbian about his paper on IV thrombolysis-treated ischemic stroke patients. Dr. Jennifer Fugate is reading our e-Pearl of the week about RRT autoregulation. In the next part of the podcast Dr. Chafic Karam interviews Dr. Josep Dalmau about common paraneoplastic syndromes causing central nervous system disorders. Over the following weeks, Dr. Karam will interview Dr. Dalmau about other paraneoplastic syndromes in neurology. All participants have disclosures.

Delayed Recall - February 2012 Feb 01, 2012

Show notes

Evaluation of post-cardiac arrest hypoxic-ischemic encephalopathy. Interview with Eelco Wijdicks.

January 31 2012 Issue Jan 31, 2012

Show notes

1) Incidence of MCI subtype differences and 2) Topic of the month: Ethics issues. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Erin Foff interviews Dr. Rosebud Roberts about her paper on the incidence of MCI subtype differences. In the next segment, Dr. Stacey Clardy is reading our e-Pearl of the week about pain in the ear. In the next part of the podcast Dr. Eric Adelman interviews Dr. Michael Russo about requests for medications used for cognitive enhancement. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Roberts and Clardy.Dr. Roberts receives research support from the NIH and Abbott.Dr. Clardy serves on the editorial team for the Neurology® Resident and Fellow Section.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected